Aim: Oxidized low-density lipoproteins (oxLDL) are formed as a result of lipid peroxidation and are highly immunogenic and proatherogenic. In this study, saliva antibodies binding to oxLDL, Porphyromonas gingivalis (Pg) and Aggregatibacter actinomycetemcomitans (Aa) were characterized and their cross-reactivity was evaluated.
In addition, the oral cavity has a rich microbiome comprising over 600 phylotypes (Dewhirst et al., 2010) . Poor oral health has been linked to atherosclerotic cardiovascular diseases, and several mechanisms have been proposed for how oral bacteria may initiate or accelerate the atherosclerotic processes in the artery intima (Gibson, Yumoto, Takahashi, Chou, & Genco, 2006; Lockhart et al., 2012) . The presence of gram negative rod bacteria such as Porphyromonas gingivalis (Pg) and Aggregatibacter actinomycetemcomitans (Aa) in the oral cavity is recognized as a risk factor for cardiovascular diseases via invasion of periodontal tissue, entering the circulation and evasion of host defence mechanisms (Hajishengallis,2015) . Circulating plasma oxLDL has also been of interest in periodontal diseases: the levels have been reported to be elevated in patients with chronic periodontitis (Schenkein & Loos,2013) , and plasma levels of oxLDL have been shown to be reduced by effective periodontal treatment (Tamaki, Tomofuji, Ekuni, Yamanaka, & Morita, 2011) .
Oxidative reactions on low-density lipoproteins are complex, and numerous oxidative end-products have not yet been fully characterized (Parthasarathy, Raghavamenon, Garelnabi, & Santanam, 2010) .
LDL oxidation plays a major role in the development of atherosclerosis, in which trapped LDL particles are oxidized in the artery wall intima by reactive oxygen species or by enzymatic modifications (Glass & Witztum,2001) . OxLDL is highly immunogenic and circulating autoantibodies against various oxidized neo-epitopes have been documented in human plasma, as well as in the plasma of animal models of atherosclerosis (Binder et al., 2005; Hörkkö et al., 2000) . The exact role of these autoantibodies in atherosclerosis has not been resolved.
Natural IgM antibodies to in vitro produced models of oxLDL, such as copper oxidized LDL (CuOx-LDL) and malondialdehyde-modified LDL (MDA-LDL), have been suggested to have atheroprotective properties (Tsiantoulas, Diehl, Witztum, & Binder, 2014) . Malondialdehyde is a small naturally occurring lipid peroxidation product and highly reactive with amino groups on various proteins, lipids and other biomolecules to form a variety of adducts (Esterbauer, Schaur, & Zollner, 1991; Wang et al., 2013) ; in the presence of acetaldehyde, for example produced by microbial oxidation of the mucosal microbiome (Kurkivuori et al., 2007) , generates malondialdehyde acetaldehyde adducts (MAA-adducts). In humans, circulating plasma IgA autoantibodies to malondialdehyde acetaldehyde-modified LDL (MAA-LDL) are shown to associate with obesity and type 2 diabetes (Vehkala et al., 2013) , whereas plasma IgM antibodies to MAA-LDL are suggested to be germ line-derived natural antibodies targeting oxidized epitopes, apoptotic cells and bacteria (Silverman,2011; Wang et al., 2013) . One of the antigenic epitopes in copper oxidized LDL is the phosphocholine (PCho) head group of oxidized phospholipids exposed on LDL surface (Binder et al., 2003) .
Using mouse monoclonal IgM antibody clones, we have previously identified cross-reactive epitopes in oxLDL, P. gingivalis (Turunen et al., 2012) and A. actinomycetemcomitans (Wang et al., 2016) . The oxidized epitopes recognized were malondialdehyde adducts of proteins and epitopes in P. gingivalis gingipain proteases (Turunen et al., 2012) . Our hypothesis was that healthy human saliva contains antibodies binding to oxLDL and that those antibodies cross-react with antibodies to P. gingivalis and A. actinomycetemcomitans.
| MATERIALS AND METHODS

| Study design and human samples
The study population consisted of 36 dental students (27 female and 9 male) at the University of Oulu, Finland; a written informed consent was obtained. The mean age was 26 years (range 21-40 years).
Resting and stimulated saliva samples were collected as follows: the resting saliva sample was collected during a 5-min collection period and the stimulated saliva sample was collected during 5-min mastication on a small paraffin block. The subjects were instructed not to eat and drink for at least 1 hr prior to the saliva collection. Blood samples were collected after an overnight fast. Plasma was separated by centrifugation at 1260 × g at +4°C for 15 min. The saliva and plasma samples were stored at −70°C for analysis. The study had been approved by the ethical committee of Northbothnia District University Hospital and followed the Declaration of Helsinki.
| Preparation of antigens for immunoassays
CuOx-LDL, MAA-LDL and MAA-BSA were prepared as previously described (Hörkkö et al., 1999; Kummu et al., 2014) .
Phosphocholine-modified BSA (PC-BSA) was purchased from Biosearch Technologies Inc. (Novato, CA, USA). Heat-killed Pg strain ATCC 33277 and recombinant domains of Pg gingipain: Rgp44 were prepared as described in previous publications (Turunen et al., 2012 (Turunen et al., , 2015 . Aggregatibacter actinomycetemcomitans (Aa) strains representing mixed serotypes of a, b, c, d, e, f and one nonserotypeable strain x (ATCC 29523, ATCC 43718, ATCC 33384, IDH 781, IDH 1705, CU 1000, C59A) were used in the study and cultured on fastidious anaerobe agar supplemented with 5%-10% blood.
Heat-killed Aa was prepared by incubation at 60°C for 1 hr in PBS.
The 60-kDa Aa chaperonin (HSP60) were prepared as previously described (Wang et al., 2016) .
| Chemiluminescence immunoassay
The levels of saliva IgA, IgG and IgM antibodies binding to various models of oxidized LDL and modified BSA were determined by chemiluminescence immunoassay as previously described (Karvonen, Päivänsalo, Kesäniemi, & Hörkkö, 2003) . Saliva samples and heat shock proteins HSP60 of Aa were also determined using chemiluminescent immunoassay. Plates were first incubated with 0.5% fish gelatin (50 μl/well) for 1 hr at RT, followed by overnight incubation of heat-inactivated bacteria (50 μl/well) 5 μg/ml in PBS-EDTA at 4°C. 1:10 dilution of saliva was used. Results are shown as relative light units (RLU) per 100 ms.
| Competitive immunoassay for antibody specificity
The specificity of human saliva antibodies was tested using liquidphase competition immunoassay. Saliva samples were incubated overnight at +4°C in the presence or absence of MAA-LDL, CuOx-LDL, Pg, Aa and native-LDL competitors (0-200 μg/ml). The immunocomplexes were pelleted by centrifugation 16,000 × g at +4°C for 30 min, and antibodies remaining in the liquid phase were analysed using the chemiluminescence immunoassay described previously (Kummu et al., 2014) .
| Measurement of apoB100 containing particles in saliva
The apolipoprotein B-100 concentration in saliva was determined using anti-apoB48/100 (Median Life Sciences, Fullerton, CA, USA)
as capture antibody and biotinylated anti apoB48/100 as detection antibody. NeutrAvidin alkaline phosphatase (1.3 mg/ml) (Thermo Scientific, Rockford, IL, USA) was used for detection. Saliva samples were diluted at 1:2. Duplicate measurements of each saliva sample were performed. A standard curve of purified human native-LDL and a control serum sample was added to each plate.
| Measurement of bacterial DNA using real-time quantitative PCR
Bacterial DNA was extracted from stimulated saliva samples by ZR 
| Plasma cholesterol measurement
Plasma total cholesterol (TC), total triglycerides and high-density lipoprotein cholesterol were determined by enzymatic methods using commercial kits (Roche Diagnostics, Mannheim, Germany). (Figure 3d-e) .
| Statistics
The levels of saliva IgM to CuOx-LDL were low, but showed association with saliva levels of IgM binding to Pg (ρ = .39, p < .02, Figure 3f ).
| Binding specificity of saliva antibodies to oxLDL
To examine the binding specificity of saliva antibody binding to oxLDL a liquid-phase competition immunoassay was performed (Figure 4 ).
First, a full-scale competition assay was performed on four different saliva samples; then, all saliva samples were tested with a fixed concentration based on the data obtained. 
| Saliva total immunoglobulin levels and normalized antigen-specific binding
The saliva total immunoglobulin levels were measured ( Figure S1 ) to estimate the normalized antigen-specific antibody binding. Resting saliva total IgA levels were significantly higher than stimulated saliva total IgA levels, but the normalized antigen-specific IgA binding to oxLDL also remained higher in the resting saliva samples ( Figure   S2A ). The saliva total IgG levels were significantly lower in the resting samples compared to stimulated samples ( Figure S1 ), and the normalized antigen-specific IgG to A. actinomycetemcomitans and P. gingivalis was significantly higher in resting saliva compared to stimulated saliva samples ( Figure S2B ). There were no differences in saliva total IgM levels between resting and stimulated samples ( Figure S2C ).
| Measurement of bacterial DNA in saliva samples
Quantitative PCR was performed to examine the amount of Pg or Aa bacterial DNA in the saliva samples (n = 36). Two saliva samples had detectable amounts of bacterial DNA, one for P. gingivalis and the other for A. actinomycetemcomitans (data not shown).
| Saliva apolipoprotein B100 and plasma cholesterol levels
Previous studies have proposed that plasma antibody titres to oxLDL associate with plasma LDL cholesterol levels (Shoji et al. 2000) .To investigate these associations in saliva, we measured apolipoprotein B100 (ApoB100) containing lipoprotein particles using sandwich immunoassay. Apolipoprotein B100 immunoassay measurement was selected, as the saliva cholesterol levels were below the detection limit of a standard detection system (see Methods). One copy of ApoB100 protein is present in each intermediate-density lipoprotein (IDL), very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) particle, but it is the primary apolipoprotein of LDL particles. The resting saliva ApoB100 concentration ranged from 3.3 to 372.9 ng/ml (mean 116.8 ng/ml) and the stimulated saliva concentration from 0.4 to 841.2 ng/ml (mean 209.5 ng/ml) ( Figure S1 ). There was no significant difference between resting and stimulated saliva ApoB100 concentrations. The saliva ApoB100 levels did not correlate with plasma ApoB100 levels, plasma TC, plasma LDL, plasma HDL or plasma triglyceride levels (data not shown). Furthermore, the saliva ApoB100 levels were not associated with saliva or plasma antibody titres to various models of oxidized LDL (data not shown). However, plasma TC and LDL cholesterol levels were associated with resting saliva IgA levels ( Figure 5 ). This serendipitous finding suggests a link between the mucosal immune system and cholesterol metabolism, and needs to be validated in a larger study cohort.
| Plasma autoantibody binding to oxLDL, A. actinomycetemcomitans and P. gingivalis
Plasma antibody binding to various models of oxLDL, Aa and Pg ( Figure S3 ) was investigated to evaluate the association to saliva antibody levels. The subjects had high plasma IgG and IgM antibody levels to oxidized epitopes, particularly to MAA-LDL. The plasma levels of IgA antibodies binding to oxidized epitopes and oral pathogens were low. No significant associations were observed between plasma and saliva antibody levels to oxLDL, Aa or Pg (data not shown). 
| DISCUSSION
Mucosal membranes, including the oral cavity, are important sites of antigenic encounter, and mucosal IgA antibodies are recognized to participate in the regulation of commensal bacteria (Brandtzaeg,2013) .
Here, we found significant levels of saliva IgA autoantibodies binding to oxidized LDL in healthy human subjects. Circulating autoantibodies to oxLDL have been linked to cardiovascular diseases, characterized by retention oxLDL in the arterial wall and activation an inflammatory response and development of atherosclerotic lesions.
In vivo oxidative modification of LDL was discovered several decades ago , and subsequently a broad spectrum of oxidized epitopes conjugated to ApoB100 have been reported and documented to induce immune response. Oxidized LDL arises in lipid peroxidation of polyunsaturated fatty acids (PUFAs) of phospholipids within LDL particles, and several different antigenic epitopes are likely to be created (Hörkkö et al., 2000) . For example, malondialdehyde (MDA), malondialdehyde acetaldehyde (MAA), 4-hydroxynonenal (4HNE-LDL), 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphoch oline (POVPC) and 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocho line (PGPC) are present in oxidatively-modified low-density lipoprotein and have also been found in atherosclerotic lesions (Hörkkö et al., 1999; Palinski et al., 1989) . These lipid peroxidation end-products also closely modify proteins other than LDL ApoB100. For example, in the present study the immunogenic epitopes for saliva IgA were also MAA-and PC-adducts in the BSA protein. This suggests that saliva IgA In panel A, each competitor was compared with nLDL using Wilcoxon test for two related samples. *p < .05, **p < .01 ***p < .001
Association between plasma total cholesterol levels, LDL cholesterol levels and resting saliva IgA levels. Associations were determined using Spearman correlation coefficient specifically recognizes oxidized lipid adducts, malondialdehyde acetaldehyde or phosphocholine adducts, and the binding is not exclusively dependent on the carrier molecule.
Circulating plasma autoantibodies to oxidative conjugates of LDL were already documented in the early 1990s (Salonen et al., 1992; Virella, Virella, Leman, Pryor, & Lopes-Virella, 1993) . Since then, numerous studies have been published, but the role of autoantibodies to oxLDL in cardiovascular disease has yielded varying results (Boullier et al., 1995; Karvonen et al., 2003; Tornvall, Waeg, Nilsson, Hamsten, & Regnstrom, 2003) . Despite this, increasing evidence shows that high levels of IgM antibodies to oxLDL are inversely associated with cardiovascular disease, suggesting a protective role for these antibodies (Karvonen et al., 2003; Tsimikas et al., 2012) . Many of the IgM-type autoantibodies binding to oxLDL are thought to be natural antibodies with high homology to germ line-encoded variable regions (Tsiantoulas et al., 2014) . Currently, it is not fully known what mechanisms are responsible for the natural IgM antibodies to confer atheroprotection, and whether there are other target antigens involved. One of the suggested mechanisms for atheroprotection has been the ability to bind to oxLDL and inhibit its uptake by macrophage scavenger receptors (Hörkkö et al., 1999) . The data of the present study revealed that human saliva contained very minimal amounts of IgM, and also antioxLDL-IgM, suggesting that natural IgM-type autoantibodies may not be dominant contributing players on mucosal surfaces and oral immunity linked to atherosclerosis and periodontal disease.
Human atherosclerotic lesions contain bacterial DNA from more than 50 bacterial species with high bacterial diversity (Ott et al., 2006 ).
As noted above, human atherosclerotic lesions are also well documented to contain oxLDL and antibodies binding to oxLDL (Tsiantoulas et al., 2014; Ylä-Herttuala et al., 1989) . Our previous studies have investigated the antigenic epitopic molecular mimicry between P. gingivalis and oxLDL using monoclonal antibodies cloned against oxLDL, and we showed cross-reactive epitopes on the hemagglutinin/adhesin domain of Pg gingipain protease and MDA-LDL (Turunen et al., 2012) .
Recently, we discovered A. actinomycetemcomitans chaperonin 60 or HSP60 as another antigenic epitope cross-reactive with oxLDL (Wang et al., 2016) . Both of these mouse monoclonal antibodies were close to germ line-encoded natural IgM antibodies. It is believed, however, that very little germ line-encoded natural IgA would be present in humans colonized with a normal microflora, as most intestinal plasma cells in humans and aged mice have highly mutated antibody genes (Barone et al., 2011; Lindner et al., 2012) . Our competitive immunoassays showed that a large portion of the polyclonal saliva IgA binding to MAA-LDL was also competed by P. gingivalis suggesting the presence of some mucosal saliva IgA antibodies to oxLDL having antigenic epitopes cross-reactive with the periodontal pathogenic bacteria
P. gingivalis.
The link between atherosclerosis and periodontal disease has been shown by several large-scale epidemiological studies (Lockhart et al., 2012; Schenkein & Loos,2013) . Various hypotheses for the observed association have been proposed, including systemic inflammation, bacteremia caused by periodontal pathogens and molecular mimicry through cross-reaction of autoantibodies (Chun, Chun, Olguin, & Wang, 2005; Lockhart et al., 2012) . Elevated levels of serum antibodies to A. actinomycetemcomitans or P. gingivalis associate with an increased risk for incident CAD and stroke (Pussinen et al., 2005) . The link between periodontal disease and the development of atherosclerosis and whether it includes molecular mimicry has not yet been fully resolved. In principle, when the structural properties of two antigens are sufficiently similar to allow them to mimic one another, the antibodies generated may cross-react. Molecular mimicry due to sequence similarities between, for example foreign and self-peptides may cause disease (Kohm, Fuller, & Miller, 2003) . Cross-reactivity of autoantibodies between periodontal bacterial lipopolysaccharides and heat shock proteins has been previously reported (Schenkein & Loos,2013) .
In atherosclerosis, vaccination with S. pneumoniae has been shown to be atheroprotective in mice and suggested to act via antibody crossreaction and molecular mimicry with oxLDL antigens (Binder et al., 2003) . Similarly, vaccination with MDA-LDL was shown to ameliorate atherosclerosis in LDLR −/− mice challenged with live P. gingivalis (Turunen et al., 2015) . The data of the present study demonstrated that there may exist cross-reactive epitopes in oxidized proteins and periodontal bacteria, and it can be further hypothesized that molecular mimicry of these epitopes induces mucosal immune responses linking cardiovascular and periodontal diseases.
Immunoglobulin A is the isotype dominating on mucosal surfaces, and also the second most abundant immunoglobulin found in plasma. Mucosal secretory IgA has dimeric structure, complexed with the ectodomain of the polymeric immunoglobulin receptor (pIgR) when transcytosed through the epithelial layer into mucosal secretions. T cells have been shown not to be an absolute requirement for IgA generation (Pabst,2012) . Both monomeric and dimeric
IgA bind to FcαRI, triggering receptor clustering and downstream signalling that activates, for example phagocytosis and antibodydependent cell-mediated cytotoxicity. Human circulation contains different classes of autoantibodies to oxLDL, including IgA isotype of autoantibodies (Wu et al., 2003) . Little is known about the origin and role of plasma anti-oxLDL-IgA, but our previous data suggested that circulating plasma IgA to oxLDL is linked to glucose metabolism, and high IgA was shown to be an independent risk factor for type 2 diabetes mellitus (Sämpi, Veneskoski, Ukkola, Kesäniemi, & Hörkkö, 2010) . The plasma levels of IgA antibodies to oxLDL have also been associated with plasma IgA antibodies to heat shock proteins HSP 60
and HPS65, and also with plasma IgA to A. actinomycetemcomitans (Buhlin et al., 2015) . The potential role(s) of anti-oxLDL-IgA in saliva calls for further studies.
In summary, significant levels of saliva IgA autoantibodies binding to oxLDL and malondialdehyde adducts were found in the saliva of healthy humans with a low salivary burden of periodontal bacteria.
These antibodies showed cross-reactive binding to P. gingivalis, and may participate in immune reactions involved in atherosclerosis and periodontal disease.
